CoChat
Sign Up
Cited by 79

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Small non-coding RNAs as important players, biomarkers and therapeutic targets in multiple sclerosis: A comprehensive overview

Piket, Eliane, Zheleznyakova, Galina Yurevna, Kular, Lara, Jagodic, Maja·2019·Journal of Autoimmunity
DOI 10.1016/j.jaut.2019.04.002
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jaut.2019.04.002

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 6 references

Research works printed but not linked: 93

  1. Compston, 2008, Multiple sclerosis, Lancet, 372, 1502, 10.1016/S0140-6736(08)61620-7 · DOI
  2. Efendi, 2015, Clinically isolated syndromes: clinical characteristics, differential diagnosis, and management, Noro psikiyatri arsivi, 52, S1, 10.5152/npa.2015.12608 · DOI
  3. Torkildsen, 2016, Disease-modifying treatments for multiple sclerosis - a review of approved medications, Eur. J. Neurol., 23, 18, 10.1111/ene.12883 · DOI
  4. Paul, 2019, Biomarkers in multiple sclerosis, Cold Spring Harbor perspectives in medicine, 9, 10.1101/cshperspect.a029058 · DOI
  5. Morris, 2014, The rise of regulatory RNA, Nat. Rev. Genet., 15, 423, 10.1038/nrg3722 · DOI
  6. Backes, 2010, A dictionary on microRNAs and their putative target pathways, Nucleic Acids Res., 38, 4476, 10.1093/nar/gkq167 · DOI
  7. Fu, 2015, Small non-coding transfer RNA-derived RNA fragments (tRFs): their biogenesis, function and implication in human diseases, Genomics & informatics, 13, 94, 10.5808/GI.2015.13.4.94 · DOI
  8. Mleczko, 2016, When small RNAs become smaller: emerging functions of snoRNAs and their derivatives, Acta Biochim. Pol., 63, 601
  9. Cech, 2014, The noncoding RNA revolution-trashing old rules to forge new ones, Cell, 157, 77, 10.1016/j.cell.2014.03.008 · DOI · Paper page
  10. Rossi, 2011, Distinct microRNA signatures in human lymphocyte subsets and enforcement of the naive state in CD4+ T cells by the microRNA miR-125b, Nat. Immunol., 12, 796, 10.1038/ni.2057 · DOI
  11. Ingwersen, 2015, Natalizumab restores aberrant miRNA expression profile in multiple sclerosis and reveals a critical role for miR-20b, Ann Clin Transl Neurol, 2, 43, 10.1002/acn3.152 · DOI
  12. Koudriavtseva, 2014, Long-term follow-up of peripheral lymphocyte subsets in a cohort of multiple sclerosis patients treated with natalizumab, Clin. Exp. Immunol., 176, 320, 10.1111/cei.12261 · DOI
  13. Gandhi, 2013, Circulating microRNAs as biomarkers for disease staging in multiple sclerosis, Ann. Neurol., 73, 729, 10.1002/ana.23880 · DOI
  14. Kacperska, 2015, Selected extracellular microRNA as potential biomarkers of multiple sclerosis activity--preliminary study, J. Mol. Neurosci. : MN, 56, 154, 10.1007/s12031-014-0476-3 · DOI
  15. Fenoglio, 2013, Decreased circulating miRNA levels in patients with primary progressive multiple sclerosis, Mult. Scler., 19, 1938, 10.1177/1352458513485654 · DOI
  16. Hecker, 2013, MicroRNA expression changes during interferon-beta treatment in the peripheral blood of multiple sclerosis patients, Int. J. Mol. Sci., 14, 16087, 10.3390/ijms140816087 · DOI
  17. De Santis, 2010, Altered miRNA expression in T regulatory cells in course of multiple sclerosis, J. Neuroimmunol., 226, 165, 10.1016/j.jneuroim.2010.06.009 · DOI
  18. Sharma, 2014, Influence of sex differences on microRNA gene regulation in disease, Biol. Sex Differ., 5, 3, 10.1186/2042-6410-5-3 · DOI
  19. Dai, 2014, Sexual dimorphism of miRNA expression: a new perspective in understanding the sex bias of autoimmune diseases, Therapeut. Clin. Risk Manag., 10, 151
  20. Munoz-Culla, 2017, Progressive changes in non-coding RNA profile in leucocytes with age, Aging, 9, 1202, 10.18632/aging.101220 · DOI
  21. Munoz-Culla, 2016, SncRNA (microRNA &snoRNA) opposite expression pattern found in multiple sclerosis relapse and remission is sex dependent, Sci. Rep., 6, 20126, 10.1038/srep20126 · DOI
  22. Baulina, 2018, Immune-related miRNA expression patterns in peripheral blood mononuclear cells differ in multiple sclerosis relapse and remission, J. Neuroimmunol., 317, 67, 10.1016/j.jneuroim.2018.01.005 · DOI
  23. Ruhrmann, 2018, Hypermethylation of MIR21 in CD4+ T cells from patients with relapsing-remitting multiple sclerosis associates with lower miRNA-21 levels and concomitant up-regulation of its target genes, Mult. Scler., 24, 1288, 10.1177/1352458517721356 · DOI
  24. Paraboschi, 2011, Genetic association and altered gene expression of mir-155 in multiple sclerosis patients, Int. J. Mol. Sci., 12, 8695, 10.3390/ijms12128695 · DOI
  25. Ridolfi, 2013, Expression and genetic analysis of MicroRNAs involved in multiple sclerosis, Int. J. Mol. Sci., 14, 4375, 10.3390/ijms14034375 · DOI
  26. McAlexander, 2013, Comparison of methods for miRNA extraction from plasma and quantitative recovery of RNA from cerebrospinal fluid, Front. Genet., 4, 83, 10.3389/fgene.2013.00083 · DOI
  27. Mestdagh, 2014, Evaluation of quantitative miRNA expression platforms in the microRNA quality control (miRQC) study, Nat. Methods, 11, 809, 10.1038/nmeth.3014 · DOI · Paper page
  28. Griffiths-Jones, 2004, The microRNA Registry, Nucleic Acids Res., 32, D109, 10.1093/nar/gkh023 · DOI
  29. McCoy, 2017, miR-155 dysregulation and therapeutic intervention in multiple sclerosis, Adv. Exp. Med. Biol., 1024, 111, 10.1007/978-981-10-5987-2_5 · DOI · Paper page
  30. Arruda, 2015, Autologous hematopoietic SCT normalizes miR-16, -155 and -142-3p expression in multiple sclerosis patients, Bone Marrow Transplant., 50, 380, 10.1038/bmt.2014.277 · DOI
  31. Waschbisch, 2011, Glatiramer acetate treatment normalizes deregulated microRNA expression in relapsing remitting multiple sclerosis, PLoS One, 6, 10.1371/journal.pone.0024604 · DOI
  32. Neudecker, 2017, Myeloid-derived miR-223 regulates intestinal inflammation via repression of the NLRP3 inflammasome, J. Exp. Med., 214, 1737, 10.1084/jem.20160462 · DOI
  33. Zhang, 2010, Secreted monocytic miR-150 enhances targeted endothelial cell migration, Mol. Cell, 39, 133, 10.1016/j.molcel.2010.06.010 · DOI
  34. Li, 2013, Microvesicle-mediated transfer of microRNA-150 from monocytes to endothelial cells promotes angiogenesis, J. Biol. Chem., 288, 23586, 10.1074/jbc.M113.489302 · DOI
  35. Sheedy, 2015, Turning 21: induction of mir-21 as a key switch in the inflammatory response, Front. Immunol., 6, 19, 10.3389/fimmu.2015.00019 · DOI · Paper page
  36. Davis, 2010, Smad proteins bind a conserved RNA sequence to promote microRNA maturation by Drosha, Mol. Cell, 39, 373, 10.1016/j.molcel.2010.07.011 · DOI
  37. Rai, 2010, Targeting of SMAD5 links microRNA-155 to the TGF-beta pathway and lymphomagenesis, Proc. Natl. Acad. Sci. U.S.A., 107, 3111, 10.1073/pnas.0910667107 · DOI
  38. Louafi, 2010, MicroRNA-155 targets SMAD2 and modulates the response of macrophages to transforming growth factor-{beta}, J. Biol. Chem., 285, 41328, 10.1074/jbc.M110.146852 · DOI · Paper page
  39. Zhang, 2018, The role of transforming growth factor beta in T helper 17 differentiation, Immunology, 155, 24, 10.1111/imm.12938 · DOI
  40. Tran, 2012, TGF-β: the sword, the wand, and the shield of FOXP3+ regulatory T cells, J. Mol. Cell Biol., 4, 29, 10.1093/jmcb/mjr033 · DOI
  41. Viglietta, 2004, Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis, J. Exp. Med., 199, 971, 10.1084/jem.20031579 · DOI
  42. Severin, 2016, MicroRNAs targeting TGFbeta signalling underlie the regulatory T cell defect in multiple sclerosis, Brain, 139, 1747, 10.1093/brain/aww084 · DOI · Paper page
  43. Huang, 2009, miR-142-3p restricts cAMP production in CD4+CD25- T cells and CD4+CD25+ TREG cells by targeting AC9 mRNA, EMBO Rep., 10, 180, 10.1038/embor.2008.224 · DOI
  44. Fayyad-Kazan, 2012, MicroRNA profile of circulating CD4-positive regulatory T cells in human adults and impact of differentially expressed microRNAs on expression of two genes essential to their function, J. Biol. Chem., 287, 9910, 10.1074/jbc.M111.337154 · DOI
  45. Rouas, 2009, Human natural Treg microRNA signature: role of microRNA-31 and microRNA-21 in FOXP3 expression, Eur. J. Immunol., 39, 1608, 10.1002/eji.200838509 · DOI
  46. Namdari, 2017, Effect of MicroRNA-21 transfection on in-vitro differentiation of human naive CD4+ T cells to regulatory T cells, Iran. J. Allergy, Asthma Immunol., 16, 235
  47. Jadidi-Niaragh, 2011, Th17 cell, the new player of neuroinflammatory process in multiple sclerosis, Scand. J. Immunol., 74, 1, 10.1111/j.1365-3083.2011.02536.x · DOI
  48. Zhang, 2014, MicroRNA-155 modulates Th1 and Th17 cell differentiation and is associated with multiple sclerosis and experimental autoimmune encephalomyelitis, J. Neuroimmunol., 266, 56, 10.1016/j.jneuroim.2013.09.019 · DOI
  49. Hosseini, 2016, Upregulation of CD4+T-cell derived mir-223 in the relapsing phase of multiple sclerosis patients, Cell J., 18, 371
  50. Du, 2009, MicroRNA miR-326 regulates TH-17 differentiation and is associated with the pathogenesis of multiple sclerosis, Nat. Immunol., 10, 1252, 10.1038/ni.1798 · DOI · Paper page
  51. Honardoost, 2014, miR-326 and miR-26a, two potential markers for diagnosis of relapse and remission phases in patient with relapsing-remitting multiple sclerosis, Gene, 544, 128, 10.1016/j.gene.2014.04.069 · DOI
  52. Cantoni, 2017, Mir-223 regulates the number and function of myeloid-derived suppressor cells in multiple sclerosis and experimental autoimmune encephalomyelitis, Acta Neuropathol., 133, 61, 10.1007/s00401-016-1621-6 · DOI · Paper page
  53. Ifergan, 2016, Cutting edge: MicroRNA-223 regulates myeloid dendritic cell-driven Th17 responses in experimental autoimmune encephalomyelitis, J. Immunol., 196, 1455, 10.4049/jimmunol.1501965 · DOI
  54. Satoorian, 2016, MicroRNA223 promotes pathogenic T-cell development and autoimmune inflammation in central nervous system in mice, Immunology, 148, 326, 10.1111/imm.12611 · DOI
  55. Liu, 2017, MicroRNA-15b suppresses Th17 differentiation and is associated with pathogenesis of multiple sclerosis by targeting O-GlcNAc transferase, J. Immunol., 198, 2626, 10.4049/jimmunol.1601727 · DOI
  56. Geekiyanage, 2011, MicroRNA-137/181c regulates serine palmitoyltransferase and in turn amyloid beta, novel targets in sporadic Alzheimer's disease, J. Neurosci. : the official journal of the Society for Neuroscience, 31, 14820, 10.1523/JNEUROSCI.3883-11.2011 · DOI · Paper page
  57. Cardo, 2013, Profile of microRNAs in the plasma of Parkinson's disease patients and healthy controls, J. Neurol., 260, 1420, 10.1007/s00415-013-6900-8 · DOI
  58. Junker, 2009, MicroRNA profiling of multiple sclerosis lesions identifies modulators of the regulatory protein CD47, Brain, 132, 3342, 10.1093/brain/awp300 · DOI · Paper page
  59. Noorbakhsh, 2011, Impaired neurosteroid synthesis in multiple sclerosis, Brain, 134, 2703, 10.1093/brain/awr200 · DOI
  60. Mandolesi, 2017, miR-142-3p is a key regulator of IL-1β-dependent synaptopathy in neuroinflammation, J. Neurosci., 37, 546, 10.1523/JNEUROSCI.0851-16.2016 · DOI
  61. De Felice, 2014, Small non-coding RNA signature in multiple sclerosis patients after treatment with interferon-beta, BMC Med. Genomics, 7, 26, 10.1186/1755-8794-7-26 · DOI
  62. Jernas, 2013, MicroRNA regulate immune pathways in T-cells in multiple sclerosis (MS), BMC Immunol., 14, 32, 10.1186/1471-2172-14-32 · DOI
  63. Irizar, 2015, Identification of ncRNAs as potential therapeutic targets in multiple sclerosis through differential ncRNA - mRNA network analysis, BMC Genomics, 16, 250, 10.1186/s12864-015-1396-5 · DOI
  64. Irizar, 2014, Transcriptomic profile reveals gender-specific molecular mechanisms driving multiple sclerosis progression, PLoS One, 9, e90482, 10.1371/journal.pone.0090482 · DOI
  65. Olsson, 2017, Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis, Nat. Rev. Neurol., 13, 25, 10.1038/nrneurol.2016.187 · DOI
  66. McHatters, 1995, Bird viruses in multiple sclerosis: combination of viruses or Marek's alone?, Neurosci. Lett., 188, 75, 10.1016/0304-3940(95)11398-G · DOI
  67. MacGregor, 1993, Complex role of gamma-herpesviruses in multiple sclerosis and infectious mononucleosis, Neurol. Res., 15, 391, 10.1080/01616412.1993.11740170 · DOI
  68. Rizzo, 2016, Serum IgG against Simian Virus 40 antigens are hampered by high levels of sHLA-G in patients affected by inflammatory neurological diseases, as multiple sclerosis, J. Transl. Med., 14, 216, 10.1186/s12967-016-0981-y · DOI
  69. Tagawa, 2016, Epstein-Barr viral miRNAs inhibit antiviral CD4+ T cell responses targeting IL-12 and peptide processing, J. Exp. Med., 213, 2065, 10.1084/jem.20160248 · DOI
  70. You, 2012, Functionally orthologous viral and cellular microRNAs studied by a novel dual-fluorescent reporter system, PLoS One, 7, e36157, 10.1371/journal.pone.0036157 · DOI
  71. Cardin, 2017, Viral MicroRNAs, host MicroRNAs regulating viruses, and bacterial MicroRNA-like RNAs, Methods Mol. Biol., 1617, 39, 10.1007/978-1-4939-7046-9_3 · DOI
  72. Grey, 2015, Role of microRNAs in herpesvirus latency and persistence, J. Gen. Virol., 96, 739, 10.1099/vir.0.070862-0 · DOI
  73. Angelini, 2013, Increased CD8+ T cell response to Epstein-Barr virus lytic antigens in the active phase of multiple sclerosis, PLoS Pathog., 9, e1003220, 10.1371/journal.ppat.1003220 · DOI
  74. Ebert, 2010, MicroRNA sponges: progress and possibilities, RNA, 16, 2043, 10.1261/rna.2414110 · DOI · Paper page
  75. Christopher, 2016, MicroRNA therapeutics: discovering novel targets and developing specific therapy, Perspect. clin. res., 7, 68, 10.4103/2229-3485.179431 · DOI · Paper page
  76. Reid, 2016, Clinical development of TargomiRs, a miRNA mimic-based treatment for patients with recurrent thoracic cancer, Epigenomics, 8, 1079, 10.2217/epi-2016-0035 · DOI
  77. Robinson, 2014, The experimental autoimmune encephalomyelitis (EAE) model of MS: utility for understanding disease pathophysiology and treatment, Handb. Clin. Neurol., 122, 173, 10.1016/B978-0-444-52001-2.00008-X · DOI · Paper page
  78. Sanders, 2016, Next-generation sequencing reveals broad down-regulation of microRNAs in secondary progressive multiple sclerosis CD4+ T cells, Clin. Epigenet., 8, 87, 10.1186/s13148-016-0253-y · DOI
  79. Keller, 2009, Multiple sclerosis: microRNA expression profiles accurately differentiate patients with relapsing-remitting disease from healthy controls, PLoS One, 4, e7440, 10.1371/journal.pone.0007440 · DOI
  80. Cox, 2010, MicroRNAs miR-17 and miR-20a inhibit T cell activation genes and are under-expressed in MS whole blood, PLoS One, 5, e12132, 10.1371/journal.pone.0012132 · DOI
  81. Zhu, 2014, miR-20b suppresses Th17 differentiation and the pathogenesis of experimental autoimmune encephalomyelitis by targeting RORgammat and STAT3, J. Immunol., 192, 5599, 10.4049/jimmunol.1303488 · DOI
  82. Weber, 2010, The microRNA spectrum in 12 body fluids, Clin. Chem., 56, 1733, 10.1373/clinchem.2010.147405 · DOI · Paper page
  83. Chen, 2008, Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases, Cell Res., 18, 997, 10.1038/cr.2008.282 · DOI · Paper page
  84. Bergman, 2016, Circulating miR-150 in CSF is a novel candidate biomarker for multiple sclerosis, Neurology(R) neuroimmunology & neuroinflammation, 3, e219, 10.1212/NXI.0000000000000219 · DOI
  85. Quintana, 2017, miRNAs in cerebrospinal fluid identify patients with MS and specifically those with lipid-specific oligoclonal IgM bands, Multiple Sclerosis Journal, 10.1177/1352458516684213 · DOI
  86. Martinelli-Boneschi, 2012, MicroRNA and mRNA expression profile screening in multiple sclerosis patients to unravel novel pathogenic steps and identify potential biomarkers, Neurosci. Lett., 508, 4, 10.1016/j.neulet.2011.11.006 · DOI
  87. Ahlbrecht, 2016, Deregulation of microRNA-181c in cerebrospinal fluid of patients with clinically isolated syndrome is associated with early conversion to relapsing-remitting multiple sclerosis, Mult. Scler., 22, 1202, 10.1177/1352458515613641 · DOI
  88. Haghikia, 2012, Regulated microRNAs in the CSF of patients with multiple sclerosis: a case-control study, Neurology, 79, 2166, 10.1212/WNL.0b013e3182759621 · DOI
  89. Regev, 2018, Identification of MS-specific serum miRNAs in an international multicenter study, Neurology(R) neuroimmunology & neuroinflammation, 5, e491, 10.1212/NXI.0000000000000491 · DOI
  90. Lecca, 2016, MiR-125a-3p timely inhibits oligodendroglial maturation and is pathologically up-regulated in human multiple sclerosis, Sci. Rep., 6, 34503, 10.1038/srep34503 · DOI
  91. Sievers, 2012, Altered microRNA expression in B lymphocytes in multiple sclerosis: towards a better understanding of treatment effects, Clin. Immunol., 144, 70, 10.1016/j.clim.2012.04.002 · DOI
  92. Munoz-Culla, 2014, Blood miRNA expression pattern is a possible risk marker for natalizumab-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients, Mult. Scler., 20, 1851, 10.1177/1352458514534513 · DOI
  93. Ebrahimkhani, 2017, Exosomal microRNA signatures in multiple sclerosis reflect disease status, Sci. Rep., 7, 14293, 10.1038/s41598-017-14301-3 · DOI

Cited by

Sorted by citations

See all 79

Metadata

Authors
Piket, E., Zheleznyakova, G. Y., Kular, L., & Jagodic, M.
Venue
Journal of Autoimmunity
Publisher
Elsevier BV
Published
2019-07
Volume
101
Pages
17-25
ISSN
0896-8411
DOI
10.1016/j.jaut.2019.04.002
Cited by
79
References
6
Language
en
Licence
Funders
  • Karolinska Institutet
  • Swedish Research Council
  • Swedish Society for Medical Research
  • Margaretha af Ugglas Foundation
  • Swedish Association
  • Swedish Brain Foundation
  • Swedish MS Foundation
  • Stockholm County Council

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review